Galderma expands physician training programs amid rising aesthetic procedure complications

Swiss pharmaceutical firm Galderma is scaling up medical training initiatives to address safety concerns stemming from the rapid growth of the unregulated aesthetic injectables market. The move highlights industry efforts to mitigate reputational and legal risks associated with botched procedures, though the efficacy of voluntary training in a fragmented global market remains uncertain.